tiprankstipranks
Medius Holdings Co., Ltd. (JP:3154)
:3154
Japanese Market
Want to see JP:3154 full AI Analyst Report?

Medius Holdings Co., Ltd. (3154) AI Stock Analysis

1 Followers

Top Page

JP:3154

Medius Holdings Co., Ltd.

(3154)

Select Model
Select Model
Select Model
Neutral 50 (OpenAI - 5.2)
Rating:50Neutral
Price Target:
¥780.00
▼(-4.53% Downside)
Action:Reiterated
Date:08/17/26
The score is mainly held back by weakening financial quality—compressed margins/ROE and especially volatile cash flow with negative free cash flow in the latest year. Technicals add pressure due to negative MACD and price trading below major moving averages. Valuation is a modest offset with a mid-range P/E and a ~2.56% dividend yield, but not enough to materially lift the overall profile.
Positive Factors
Steady Revenue Growth
Sustained revenue expansion indicates resilient demand for medical devices and related supplies. Serving hospitals and clinics provides an established healthcare customer base, supporting business continuity over the medium term.
Negative Factors
Compressed Profitability
Very thin net margins and declining returns on equity leave limited room to absorb cost inflation or execution errors. Persistently weak profitability could constrain reinvestment, reduce shareholder returns and limit the benefits of revenue growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
Sustained revenue expansion indicates resilient demand for medical devices and related supplies. Serving hospitals and clinics provides an established healthcare customer base, supporting business continuity over the medium term.
Read all positive factors

Medius Holdings Co., Ltd. (3154) vs. iShares MSCI Japan ETF (EWJ)

Medius Holdings Co., Ltd. Business Overview & Revenue Model

Company Description
Medius Holdings Co., Ltd. is a Japanese enterprise deeply embedded in the healthcare sector. The company's operations involve the distribution of a diverse range of medical devices, encompassing fundamental consumables such as syringes and gauze, ...
How the Company Makes Money
Medius Holdings primarily makes money through the sale and distribution of medical devices and related medical consumables to healthcare providers (e.g., hospitals and clinics). Revenue is generated when the company procures products from manufact...

Medius Holdings Co., Ltd. Financial Statement Overview

Summary
Revenue has grown steadily, and leverage is moderate with improving debt-to-equity. However, profitability has compressed (net margin ~0.3% in 2026 vs. ~0.8% in 2021–2022; ROE down to ~4.6%), and cash generation is a key weakness with volatile operating cash flow and negative free cash flow in 2026.
Income Statement
56
Neutral
Balance Sheet
60
Neutral
Cash Flow
39
Negative
BreakdownJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue302.34B288.69B259.79B239.05B221.69B
Gross Profit35.82B33.30B31.09B29.31B27.42B
EBITDA4.01B4.77B3.86B4.27B3.80B
Net Income944.09M1.38B1.12B1.50B1.87B
Balance Sheet
Total Assets112.59B113.54B115.34B97.73B93.15B
Cash, Cash Equivalents and Short-Term Investments10.05B14.33B13.64B10.33B9.11B
Total Debt18.39B21.89B24.57B19.70B17.98B
Total Liabilities91.85B93.06B95.60B79.15B75.84B
Stockholders Equity20.74B20.48B19.74B18.57B17.31B
Cash Flow
Free Cash Flow-373.71M5.26B261.12M300.65M-8.49B
Operating Cash Flow374.23M7.01B1.92B1.22B-3.90B
Investing Cash Flow-1.26B-2.51B-2.67B-862.94M-4.82B
Financing Cash Flow-3.40B-3.47B4.01B862.90M5.21B

Medius Holdings Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price817.00
Price Trends
50DMA
799.40
Positive
100DMA
810.09
Negative
200DMA
800.93
Positive
Market Momentum
MACD
4.26
Negative
RSI
57.23
Neutral
STOCH
60.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3154, the sentiment is Positive. The current price of 817 is above the 20-day moving average (MA) of 793.40, above the 50-day MA of 799.40, and above the 200-day MA of 800.93, indicating a bullish trend. The MACD of 4.26 indicates Negative momentum. The RSI at 57.23 is Neutral, neither overbought nor oversold. The STOCH value of 60.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3154.

Medius Holdings Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
¥1.04T32.1819.68%1.36%21.16%157.04%
72
Outperform
¥83.64B13.352.83%6.53%52.32%
70
Outperform
¥158.32B23.142.73%9.94%10.50%
66
Neutral
¥275.19B114.910.98%2.66%14.87%-55.19%
52
Neutral
¥11.29B-15.983.85%-5.34%-152.53%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
¥18.01B19.222.46%4.73%-31.38%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:3154
Medius Holdings Co., Ltd.
816.00
7.90
0.98%
JP:7747
Asahi Intecc Co
3,862.00
1,376.15
55.36%
JP:7716
Nakanishi
3,165.00
1,113.82
54.30%
JP:7702
JMS Co., Ltd.
458.00
25.79
5.97%
JP:7730
Mani, Inc.
1,614.00
372.84
30.04%
JP:7979
Shofu Inc.
2,317.00
396.34
20.64%

Medius Holdings Co., Ltd. Corporate Events

Medius Holdings Sees Profit Drop but Projects Earnings Recovery in FY2027
Aug 12, 2026
Medius Holdings Co., Ltd., a Tokyo Prime Market-listed company, reported consolidated net sales of ¥302.3 billion for the fiscal year ended June 30, 2026, a 4.7% increase year on year, while operating profit and ordinary profit declined sligh...
Medius Holdings Announces Corrections to Previously Released Financial Results
Aug 12, 2026
Medius Holdings Co., Ltd., a Prime Market-listed Japanese company, has notified investors that previously released financial results contain errors that require correction. The firm has directed stakeholders to its Japanese disclosure materials fo...
Medius Holdings Names Hiroyuki Akutagawa as New President and Representative Director
Jun 25, 2026
Medius Holdings Co., Ltd. announced that President and Representative Director Yasuhiko Ikeya will resign from his role effective August 1, 2026, due to health reasons, and will assume the post of non-representative Chairman. The Board of Director...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 17, 2026